

1 *Integrative omics identifies conserved and pathogen-specific*  
2 *responses of sepsis-causing bacteria*

3  
4 **Supplementary Figures and Tables**

5  
6 Andre Mu<sup>^,1,2</sup>, William P. Klare<sup>^,3</sup>, Sarah L. Baines<sup>^,1</sup>, C.N. Ignatius Pang<sup>^,4,5</sup>, Romain  
7 Guerillot<sup>^,1</sup>, Nichaela Harbison-Price<sup>^,6,7</sup>, Nadia Keller<sup>6</sup>, Jonathan Wilksch<sup>1</sup>, Nguyen Thi  
8 Khanh Nhu<sup>6,7</sup>, Minh-Duy Phan<sup>6,7</sup>, Bernhard Keller<sup>6,7</sup>, Brunda Nijagal<sup>8,9</sup>, Dedreia Tull<sup>8</sup>,  
9 Saravanan Dayalan<sup>8</sup>, Hwa Huat Charlie Chua<sup>8</sup>, Dominik Skoneczny<sup>8</sup>, Jason Koval<sup>4</sup>,  
10 Abderrahman Hachani<sup>1</sup>, Anup D. Shah<sup>10</sup>, Nitika Neha<sup>10</sup>, Snehal Jadhav<sup>10</sup>, Sally R. Partridge<sup>11</sup>,  
11 Amanda J. Cork<sup>6,7</sup>, Kate Peters<sup>6,7</sup>, Olivia Bertolla<sup>6,7</sup>, Stephan Brouwer<sup>6,7</sup>, Steven J. Hancock<sup>6</sup>,  
12 Laura Álvarez-Fraga<sup>6</sup>, David M.P. De Oliveira<sup>6,7</sup>, Brian Forde<sup>6</sup>, Ashleigh Dale<sup>3</sup>, Warasinee  
13 Mujchariyakul<sup>1</sup>, Calum Walsh<sup>1</sup>, Ian Monk<sup>1</sup>, Anna Fitzgerald<sup>12</sup>, Mabel Lum<sup>12</sup>, Carolina Correa-  
14 Ospina<sup>4</sup>, Piklu Roy Chowdhury<sup>13</sup>, Robert G. Parton<sup>7,14</sup>, James De Voss<sup>6</sup>, James Beckett<sup>6</sup>,  
15 Francois Monty<sup>15</sup>, Jessica McKinnon<sup>13</sup>, Xiaomin Song<sup>16</sup>, John R. Stephen<sup>17</sup>, Marie Everest<sup>17</sup>,  
16 Matt I. Bellgard<sup>18</sup>, Matthew Tinning<sup>17</sup>, Michael Leeming<sup>8</sup>, Dianna Hocking<sup>1</sup>, Leila Jebeli<sup>1</sup>,  
17 Nancy Wang<sup>1</sup>, Nouri Ben Zakour<sup>11</sup>, Serhat A. Yasar<sup>4</sup>, Stefano Vecchiarelli<sup>4</sup>, Tonia Russell<sup>4</sup>,  
18 Thiri Zaw<sup>16</sup>, Tyrone Chen<sup>19</sup>, Don Teng<sup>8,9</sup>, Zena Kassir<sup>4</sup>, Trevor Lithgow<sup>20</sup>, Adam Jenney<sup>20</sup>,  
19 Jason N. Cole<sup>21</sup>, Victor Nizet<sup>21</sup>, Tania C. Sorrell<sup>11</sup>, Anton Y. Peleg<sup>20</sup>, David L. Paterson<sup>22</sup>, Scott  
20 A. Beatson<sup>6</sup>, Jemma Wu<sup>16</sup>, Mark P. Molloy<sup>16</sup>, Anna E. Syme<sup>23</sup>, Robert J.A. Goode<sup>10,24</sup>, Adam  
21 A. Hunter<sup>18</sup>, Grahame Bowland<sup>18</sup>, Nicholas P. West<sup>\*,6</sup>, Marc R. Wilkins<sup>\*,4</sup>, Steven P.  
22 Djordjevic<sup>\*,13</sup>, Mark R. Davies<sup>\*,1</sup>, Torsten Seemann<sup>\*,1</sup>, Benjamin P. Howden<sup>\*,1</sup>, Dana  
23 Pascovici<sup>\*,16</sup>, Sonika Tyagi<sup>\*,19</sup>, Ralf B. Schittenhelm<sup>\*,10</sup>, David P. De Souza<sup>\*,8</sup>, Malcolm J.  
24 McConville<sup>\*,8,9</sup>, Jonathan Iredell<sup>\*,11</sup>, Stuart J. Cordwell<sup>\*,3</sup>, Richard A. Strugnell<sup>\*,1</sup>, Timothy P.  
25 Stinear<sup>\*,1</sup>, Mark A. Schembri<sup>\*,6,7</sup>, Mark J. Walker<sup>\*,+,6,7</sup>

26 <sup>^,\*</sup>**Contributed equally to this work**

27 **+Corresponding author:** Professor Mark J. Walker, Institute for Molecular Bioscience, The  
28 University of Queensland, Brisbane, Queensland, Australia; mark.walker@uq.edu.au

29 **Author addresses:**

30 <sup>1</sup>Department of Microbiology and Immunology, The University of Melbourne at the Peter  
31 Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia

32 <sup>2</sup>Wellcome Sanger Institute, Hinxton, United Kingdom

33 <sup>3</sup>Charles Perkins Centre and School of Life and Environmental Sciences, The University of  
34 Sydney, Sydney, New South Wales , Australia

35 <sup>4</sup>Ramaciotti Centre for Genomics, School of Biotechnology and Biomolecular Sciences,  
36 University of New South Wales, Sydney, New South Wales, Australia

37 <sup>5</sup>Bioinformatics Group, Children's Medical Research Institute, Faculty of Medicine and  
38 Health, The University of Sydney, New South Wales, Australia

39 <sup>6</sup>Australian Infectious Diseases Research Centre and School of Chemistry and Molecular  
40 Biosciences, The University of Queensland, Brisbane, Queensland, Australia

41 <sup>7</sup>Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland,  
42 Australia

43 <sup>8</sup>Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and  
44 Biotechnology Institute, University of Melbourne, Melbourne, Victoria, Australia

45 <sup>9</sup>Metabolomics Australia, Bio21 Institute, The University of Melbourne, Melbourne, Australia

46 <sup>10</sup>Monash Proteomics and Metabolomics Facility, Monash Biomedicine Discovery Institute,  
47 Monash University, Melbourne, Victoria, Australia

48 <sup>11</sup>Centre for Infectious Diseases and Microbiology, Westmead Hospital/ Westmead Institute,  
49 and Sydney ID, University of Sydney, New South Wales, Australia

50 <sup>12</sup>Bioplatforms Australia Ltd., Sydney, New South Wales, Australia

51 <sup>13</sup>Australian Institute for Microbiology and Infection, University of Technology Sydney, New  
52 South Wales, Australia

53 <sup>14</sup>Centre for Microscopy and Microanalysis, The University of Queensland, Brisbane,  
54 Queensland, Australia

55 <sup>15</sup>Australian Biocommons, The University of Melbourne, Melbourne, Victoria, Australia

56 <sup>16</sup>Australian Proteome Analysis Facility, Macquarie University, Sydney, Australia

57 <sup>17</sup>Australian Genome Research Facility Ltd., Melbourne, Victoria, Australia

58 <sup>18</sup>Center for Comparative Genomics, Murdoch University, Perth, Western Australia, Australia

59 <sup>19</sup>Department of Infectious Diseases, Monash University, Melbourne, Victoria, Australia

60 <sup>20</sup>Centre to Impact AMR and Infection Program, Monash Biomedicine Discovery Institute and  
61 Department of Microbiology, Monash University, Melbourne, Victoria, Australia

62 <sup>21</sup>Department of Pediatrics, University of California at San Diego School of Medicine, La Jolla,  
63 CA 92093, USA; Skaggs School of Pharmaceutical Sciences, University of California at San  
64 Diego, La Jolla, CA 92093, USA.

65 <sup>22</sup>Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia

66 <sup>23</sup>Melbourne Bioinformatics, The University of Melbourne, Melbourne, Australia

67 <sup>24</sup>Present Address: Commonwealth Scientific and Industrial Research Organisation, Clayton,  
68 Australia

69

70

71

72


73

74


75

*E. coli*


**MS14387**




**MS14386**



**MS14384**




**B36**






*K. variicola*


AJ292




AJ055



04153260899A




03-311-0071




*K. pneumoniae*

KPC2



AJ218



79

80

81

82


83

84


85

*S. aureus*


BPH2986




BPH2900




BPH2947



BPH2760



BPH2819



86

87

88


89

90


91

*S. pyogenes*


SP444




PS006




HKU419



PS003



5448



92

93

94 **Supplementary Figure 1.** Quality control analysis of RNAseq data for each strain included in

95 this study. The following is reported across the six biological replicates per strain for each

96 species when grown in RPMI and exposed to human sera: (A) the number of mapped reads;


97 (B) read counts per million and (C) normalised read counts per million with boxplot markers

98 indicating the median of the data, a box indicating the interquartile ranges, whiskers indicating

99 the minimum and maximum values, and outliers highlighted by individual dots; (D) multi-


100 dimensional scaling plot visualising the separation in samples by growth in RPMI vs., exposure  
101 to human sera along the first dimension; (E) correlation plot of transcriptomic data; (F)  
102 detection of outlier samples with boxplot markers indicating the median of the data, a box  
103 indicating the interquartile ranges, whiskers indicating the minimum and maximum values, and  
104 outliers highlighted by individual dots; and (G) heatmap distribution of gene counts.





106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130

*Supplementary Figure 2. Functional and metabolic pathway enrichment analysis to assess the shared transcriptome response to serum.* Shapes and colours represent normalised enrichment scores and indicate up (blue) and down (red) regulated functions or pathways in serum. Only enriched Gene Ontology terms and KEGG metabolic pathways found to be significantly enriched in all strains of a species or 50% of all strains are represented.



131

132 *Supplementary Figure 3. Carbamate kinase augments growth of S. pyogenes in human*

133 *serum.* (A) The arginine deiminase pathway catalyses the conversion of arginine to ornithine

134 and carbamoyl phosphate, enabling carbamate kinase mediated ATP, carbon dioxide and

135 ammonia production. (B) Growth rates of GAS 5448 wild type, GAS 5448 $\Delta$ *arcC*, and GAS

136 5448 $\Delta$ *arcC* complemented with wild type *arcC* in human serum. The data corresponds with

137 mean ( $\pm$  SEM) absorbance at 600 nm from three independent biological experiments

138 undertaken in technical triplicate. (C) Area-under-the-curve (AUC) for each growth curve was

139 calculated using the R package Growthcurver to compute AUC. Significance testing was

140 performed using Student's unpaired, two-sided t-test, with the null with the null hypothesis (no  
141 difference between mean AUC values) rejected for  $p < 0.05$  (\*\*\*)  $p < 0.001$ ) (n=3).


142

143

144

145





146

147 *Supplementary Figure 4. wcaF and carB gene expression enhances E. coli survival in*

148 *human serum.* Survival of (A) *E. coli* B36, B36 $\Delta$ carB, B36 $\Delta$ wcaF, and (B) *E. coli* EC958,

149 EC958 $\Delta$ carB, EC958 $\Delta$ wcaF in human serum. The data represents the mean ( $\pm$  SEM)


150 absorbance at 600 nm from three independent biological experiments undertaken in technical

151 triplicate.


152

*E. coli*


MS14387




MS14386




MS14384




B36




*K. variicola*  
AJ292




AJ055




04153260899A




03-311-0071








*K. pneumoniae*  
KPC2




AJ218










167 **Supplementary Figure 5. Quality control analysis of metabolomic data for each strain**  
 168 **included in this study.** The following is reported across the six biological replicates per strain

169 for each species when grown in RPMI and exposed to human sera: sample coefficient of  
170 variation, number of proteins per sample, samples plotted on PCA sample space, and  
171 normalised protein intensities with boxplot markers indicating the median of the data, a box  
172 indicating the interquartile ranges, whiskers indicating the minimum and maximum values, and  
173 outliers highlighted by individual dots.

174


175  
176  
177  
178  
179  
180  
181  
  
186  
187  
188  
189  
190  
191



192 **Supplementary Figure 6. Scatter plots showing the correlation between the DDA and**  
193 **DIA/SWATH proteomic datasets of the 20 pathogens.** The log<sub>2</sub> fold changes of the two  
194 datasets are plotted against each other with the DDA datasets shown on the x-axis and the  
195 DIA/SWATH datasets on the y-axis.

196  
197

198  
 199  
 200  
 202  
 203  
 205  
 206  
 209  
 210  
 212  
 213  
 214





216 ***Supplementary Figure 7. Data-independent acquisition/sequential window acquisition of all***  
217 ***theoretical mass spectra (DIA/SWATH) mass spectrometry to assess the impact of serum***  
218 ***exposure on proteome within the different species.*** (A) UpSet plots representing the shared  
219 and distinctive proteome responses across strains of the same species. Only proteins with  
220 significant differential expression after exposure to human serum are represented (FDR<0.05;  
221 |log<sub>2</sub> fold change|>1). (B) Multidimensional scaling plots of the core-proteins responses across  
222 strains of the same species demonstrating a clear separation of serum exposed samples for all  
223 species. See Fig. 4 legend for more detailed explanation of the figures.  
224




226 ***Supplementary Figure 8. Functional and metabolic pathway enrichment analysis to assess***  
227 ***the shared proteome response to serum (DDA mass spectrometry).*** Shapes and colours  
228 represent normalised enrichment scores and indicate up (blue) and down (red) regulated  
229 functions or pathways in serum (two-sided Fisher's exact test). Only enriched Gene Ontology  
230 terms and KEGG metabolic pathways found to be significantly enriched in all strains of a  
231 species or 50% of all strains are represented.  
232



258 ***Supplementary Figure 9. Functional and metabolic pathway enrichment analysis to assess***  
259 ***the shared proteome response to serum (DIA/SWATH mass spectrometry).*** Shapes and  
260 colours represent normalised enrichment scores and indicate up (blue) and down (red)  
261 regulated functions or pathways in serum (two-sided Fisher's exact test). Only enriched Gene  
262 Ontology terms and KEGG metabolic pathways found to be significantly enriched in all strains  
263 of a species or 50% of all strains are represented.

264

265



267

268 **Supplementary Figure 10. Growth kinetics of *S. aureus* in 50% human serum using *S.***


269 ***aureus* strain JE2 wild type compared to the JE2 *ΔisdI* transposon mutant.** (A) Growth in

270 RPMI only. (B) Growth in RPMI with 50% heat-treated human serum (v/v). The data in (A)

271 and (B) represents the mean ( $\pm$  SEM) absorbance at 600 nm from three independent biological


272 experiments. (C) Comparison of mean area-under-the-curve (AUC) values for each of the three

273 biological replicates depicted in (B) showing a significant difference between mutant and wild  
274 type (two-sided Student's unpaired t-test \*  $p=0.03$ ).





278 ***Supplementary Figure 11. Functional and metabolic pathway enrichment analysis to assess***  
279 ***the shared metabolome response to serum (GC-MS).*** Shapes and colours represent normalised  
280 enrichment scores and indicate up (blue) and down (red) regulated functions or pathways in  
281 serum. Only enriched Gene Ontology terms and KEGG metabolic pathways found to be  
282 significantly enriched in all strains of a species or 50% of all strains are represented.  
283






JUS

304 **Supplementary Figure 12. Stress survival assays following exposure to serum.** (A) *K.*  
 305 *pneumoniae* KPC2; (B) *S. pyogenes* HKU419; (C) *E. coli* B36; (D) *S. aureus* BPH2900 were  
 306 incubated in RPMI or serum (5 mL each) for 2 hrs. Cells were collected and then exposed to  
 307 either (each graph, left) 150 mM NaCl (osmotic stress), (middle) 5 mM H<sub>2</sub>O<sub>2</sub> (oxidative stress),  
 308 or (right) 50 μM deferoxamine (DF; iron limitation stress) for 1 hr at 37°C, and survival




309 determined by enumeration of CFU. Error bars indicate the mean standard error from 6  
310 biological replicates for all strains and conditions test – except for *S. aureus* BPH2900 tested  
311 at 5 mM H<sub>2</sub>O<sub>2</sub> in sera and RPMI which had 8 biological replicates – and statistical significance  
312 was determined using two-way ANOVA, \*  $p < 0.05$ ; \*\*  $p < 0.01$ , \*\*\*\* $p < 0.0001$ ; Holm-Šidák  
313 *test*.  
314

**A** *E. coli* B36




0 minutes






5 minutes



120 minutes



300 minutes






315

316




317

**B** *K. pneumoniae* KPC2




0 minutes






5 minutes



120 minutes






300 minutes






**C** *S. aureus* BPH2900




0 minutes






5 minutes



120 minutes






300 minutes








**D** *S. pyogenes* HKU419




0 minutes






5 minutes



120 minutes



300 minutes



320

321 *Supplementary Figure 13. Quantification of the interaction of bacterial sepsis strains with*

322 *cholesterol over time.* Indicated bacterial strains were grown for 0 min, 5 min, 120 min or

323 300 min in RPMI in the presence of 10µM TopFluor-cholesterol (a fluorescent cholesterol

324 analogue). (A-D) Overview (left panel) and close-ups (centre panel) of clinical strains *E. coli*

325 B36 (A), *K. pneumoniae* KPC2 (B), *S. aureus* BPH2900 (C) and *S. pyogenes* HKU419 (D).  
326 Experiments were done at least in three independent biological replicates for time points at  
327 120 min for all strains. For the other time points (i.e., 0 min, 5 min, and 300 min) the  
328 experiment as performed with at least one independent biological replicate for *K. pneumoniae*  
329 KPC2, *E. coli* B36, and *S. aureus* BPH2900, and two independent biological replicates for *S.*  
330 *pyogenes* HKU419. TopFluor-cholesterol is shown in green (GFP), bacteria in red (alexa555)  
331 and nuclei in blue (DAPI). Right panel shows the histogram of the fluorescence intensity of  
332 one representative bacterium with the cross-section marked in the close-up image. Colours in  
333 the histogram are adjusted to microscope pictures with bacteria in red, nuclei in blue and  
334 TopFluor-cholesterol in green.

335

336



337 **Supplementary Table 1.** Primers used in this study.

338

<b>GAS 5448</b>	
<i>arcC</i> deletion replacement	
<b>Primers</b>	<b>Sequence 5'→3'</b>
CKF	GGGAATTCCAGCTGTTGTCACTCAAGT
CKR	GGGGATCCACACCAGTCAGGG
CKF-Up	ATGACGAAACAAAAAATCGTAGTCGCA
CKR-Down	TTACCCTGCGATAATTTGTGTTCCAG
ErmF	ATGAACAAAAATATAAAATATTCTCAAAC
ErmR	TTATTTCTCCCGTTAAATAATAGATA
<i>arcC</i> complementation	
<b>Primers</b>	<b>Sequence 5'→3'</b>
arcC_F-Up	GTCGTCAGACTGATGGGCCCTAAAGATGCTCCCGATG
arcC_R-Down	CATAACCTGAAGGAAGATCTCATATTAACAACAAGGCCTTC
arcC_F	AGGAGTAATTATGACGAAACAAAAAATCG
arcC_R	ATCCTCTTGATTACCCTGCGATAATTTG
<i>E. coli</i> B36 and <i>E. coli</i> EC958	
<b>Primers</b>	<b>Sequence 5'→3'</b>
3518-2394wcaF-Fwsc	AGCGAACCAGATAACGGTA
3519-2394wcaF-Fwup	ACTCGGGCGATATTTTTTCAT
3520-2394wcaF-Rvup	GGAATAGGAACTAAGGAGGACGGCACCAGAGAATCCACTTA
3521-2394wcaF-Fwdn	CCTACACAATCGCTCAAGACTAAATTCAAAAAATACAGAG
3522-2394wcaF-Rvdn	AACGGCGTGGTCTCTTTCTG
3523-2394wcaF-Rvsc	CCGTAGGATTCGCGGTAGTT
11474_carB_Fwup	GTCGCCTGACCATCGTTC
11475_carB_Rvup	GGAATAGGAACTAAGGAGGATGGCATGGCTCTTTTACTCC
11476_carB_Fwdn	CCTACACAATCGCTCAAGACGCGCAGATCAAATAATAGCG
11477_carB_Rvdn	CTGCTCGTAAGGCATCAGACT
11478_carB_Fwsc	CAAGGGAGCTGGACACTG
11479_carB_Rvsc	CAACTTCGTTACTTACGGCC
3746-Cm.3a	TCCTCCTTAGTTCCTATTCC
3747-Cm.4a	GTCTTGAGCGATTGTGTAGG

339

340

341

342

343